Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
262000 263000 272500 267000 275500 Last
505510 416684 576273 354210 573926 Volume
-2.06% +0.38% +3.61% -2.02% +3.18% Change
Estimated financial data (e)
Sales 2021 2 051 B 1,74 B 1,74 B
Net income 2021 644 B 0,55 B 0,55 B
Net cash position 2021 283 B 0,24 B 0,24 B
P/E ratio 2021 56,1x
Yield 2021 0,01%
Sales 2022 2 504 B 2,12 B 2,12 B
Net income 2022 807 B 0,68 B 0,68 B
Net cash position 2022 967 B 0,82 B 0,82 B
P/E ratio 2022 47,1x
Yield 2022 0,01%
Capitalization 37 636 B 31 904 M 31 916 M
EV / Sales 2021 18,2x
EV / Sales 2022 14,6x
Nbr of Employees 2 034
Free-Float 76,0%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Ratings of Celltrion, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CELLTRION, INC.
04:28aSouth Korea approves Celltrion's COVID-19 treatment for use
RE
08/13MARKET CHATTER : Brazil Approves Celltrion's COVID-19 Treatment for Emergency Us..
MT
08/06MARKET CHATTER : Celltrion, TriLink BioTechnologies Enter Deal to Develop mRNA V..
MT
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars ..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulize..
CI
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
07/14KOSPI COMPOSITE INDEX : South Korean Stocks End Two-Day Winning Streak over Infl..
MT
07/13MARKET CHATTER : Celltrion's COVID-19 Antibody Treatment Lowers Severe Infection..
MT
06/30EU Adds Eli Lilly's Antibodies, Four Other Drugs in COVID-19 Therapeutics Por..
MT
06/29EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
RE
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/15MARKET CHATTER : Celltrion's COVID-19 Treatment Reduces Viral Load
MT
06/14Celltrion Rallies After Positive Data on Covid-19 Treatment
DJ
06/13CELLTRION : says trial shows antibody COVID-19 treatment to be safe and effectiv..
RE
06/07MARKET CHATTER : Celltrion to Invest $47 Million in British Biotech Firm Iksuda ..
MT
More news
News in other languages on CELLTRION, INC.
07/20MÄRKTE ASIEN/US-Vorgaben und Konjunktursorgen dämpfen Kauflust
06/15MÄRKTE ASIEN/Uneinheitlich - Sydney und Seoul auf Rekordjagd
06/15MÄRKTE ASIEN/Tokio und Sydney fest - Schanghai und Hongkong leichter
06/14MÄRKTE ASIEN/Tokio freundlich - Rekordhoch in Seoul
05/07VACCINI : Ue; aperti a dialogo, Usa sblocchi export (Stampa)
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 275 500,00 KRW
Average target price 329 400,00 KRW
Spread / Average Target 19,6%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-23.26%31 021
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.91%49 407
SEAGEN INC.-12.32%27 940
PHARMARON BEIJING CO., LTD.83.56%24 534